加速器质谱微示踪研究评估YH4808吸收的首过效应
本研究采用14C标记YH4808微示踪剂(80 μg,11.8 kBq)与200 mg非放射性口服药物同时给药,测定绝对生物利用度并评估药物基因组学对口服吸收的影响。结果显示绝对生物利用度低且变异大(均值10.1%,范围2.3-19.3%),口服后活性代谢物M3和M8生成量分别比静脉给药高22.6倍和38.5倍。携带CHST3、SLC15A1和SULT1B1基因变异的受试者中,口服剂量进入肠壁并进入门循环的比例更高。
要点
- YH4808绝对生物利用度低且变异大,均值10.1%(范围2.3-19.3%)。
- 口服后活性代谢物M3和M8生成量分别比静脉给药高22.6倍和38.5倍。
- CHST3、SLC15A1和SULT1B1基因变异影响YH4808口服吸收过程。
核心结论
- YH4808口服绝对生物利用度低且高度变异,首过效应显著影响其吸收。
- 液相色谱-加速器质谱联用(LC+AMS)可用于早期临床药物开发中构建高信息量药代动力学知识库。
研究设计与样本
- 14C标记YH4808以80 μg(11.8 kBq或320 nCi)微示踪剂静脉给药,同时口服非放射性YH4808 200 mg。
- 研究测定绝对生物利用度并评估药物基因组学对口服吸收的影响。
主要发现
- 绝对生物利用度均值10.1%,范围2.3-19.3%。
- 口服给药后活性代谢物M3和M8的生成量分别比静脉给药高22.6倍和38.5倍。
- 携带CHST3、SLC15A1和SULT1B1基因变异的受试者中,口服剂量进入肠壁并进入门循环的比例更大。
临床怎么用
- 临床用药需关注YH4808口服生物利用度低且个体差异大的特点。
- 对于携带CHST3、SLC15A1和SULT1B1基因变异的患者,可能需要考虑吸收差异对疗效的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
14 C-labeled YH4808, a novel potassium-competitive acid blocker, was intravenously administered as a microtracer at 80 μg (11.8 kBq or 320 nCi) concomitantly with the nonradiolabeled oral drug at 200 mg to determine the absolute bioavailability and to assess the effect of pharmacogenomics on the oral absorption of YH4808. The absolute bioavailability was low and highly variable (mean, 10.1%; range, 2.3-19.3%), and M3 and M8, active metabolites of YH4808, were formed 22.6- and 38.5-fold higher after oral administration than intravenous administration, respectively. The product of the fraction of an oral YH4808 dose entering the gut wall and the fraction of YH4808 passing on to the portal circulation was larger in subjects carrying the variants of the CHST3, SLC15A1, and SULT1B1 genes. A combined LC+AMS is a useful tool to construct a rich and highly informative pharmacokinetic knowledge core in early clinical drug development at a reasonable cost.
引用
- Kim A, Yu BY, Dueker SR, et al. An Accelerator Mass Spectrometry-Enabled Microtracer Study to Evaluate the First-Pass Effect on the Absorption of YH4808. Clin Pharmacol Ther. 2017. PMID: 28214288. doi:10.1002/cpt.672
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。